Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study.
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025 May 15; 145(20):2303-2311.
PMID: 39938019
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma.
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nat Commun. 2025 May 06; 16(1):4205.
PMID: 40328775
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study. Blood Adv. 2025 Apr 30.
PMID: 40305658
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma.
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Apr 25.
PMID: 40288610
Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma.
Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma. bioRxiv. 2025 Mar 15.
PMID: 40161759
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis.
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025 Mar 11; 9(5):1232-1241.
PMID: 39657136
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review. Target Oncol. 2025 Mar; 20(2):217-234.
PMID: 40035913
Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.
Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma. Blood. 2025 Feb 12.
PMID: 39938007
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer. 2025 Feb 09; 13(2).
PMID: 39924174
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial.
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025 01 11; 405(10473):127-136.
PMID: 39798981